Page 5 of 8, showing 50 records out of 368 total, starting on record 201, ending on 250
| Publication |
Category |
Year |
|
149. Labrie, F. (1992) Stratégie efficace et peu coûteuse pour la détection du cancer de la prostate à un stade précoce alors que la guérison est possible. Médecine/Sciences, 8: 703-706. |
Prostate Cancer |
1992 |
|
150. Labrie, F., Dupont, A., Cusan, L., Gomez, J., Emond, J., Monfette, G. (1992) Combination therapy with Flutamide and medical (LHRH agonist) or surgical castration in advanced prostate cancer (8-year clinical experience) and extension to early stages of the diseases, in: Carpi, A., Sagripanti, A. et Mittermayer, eds: Progress in Clinical Oncology, Italy, Sympomed Verlag, pp 278-293. |
Prostate Cancer |
1992 |
|
151. Labrie, F., Dupont, A., Cusan, L., Suburu, E.R., Gomez, J.L., Thibault, M.M., Tremblay, M. (1992) Perspectives dans le diagnostic et le traitement du cancer de la prostate au stade précoce, in: Bonjour, J.P., Gayraud, M.,Guillevin, L. et Rizzoli, R., eds: Nouvelles statégies thérapeutiques en cancérologie, rapports présentés au XLVIIIe Congrès Français de Médecine, Montréal 1991, Alertes carcinologiques, pp 25-44. |
Prostate Cancer |
1992 |
|
152. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Tremblay, M., Gomez, J.L., Emond, J. (1992) Serum prostate specific antigen (PSA) as prescreening test for prostate cancer. J. Urol., 147: 846-851. |
Prostate Cancer |
1992 |
|
153. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1992) Blockade of androgen action by combined treatment with a pure antiandrogen (Flutamide) and a 5α-reductase inhibitor (4-MA), in: Giuliani, L. et Puppo, P., eds: Urology, Bologna, Monduzzi Editore, pp 605-610. |
Prostate Cancer |
1992 |
|
154. Pinault, S., Têtu, B., Gagnon, J., Monfette, G., Dupont, A., Labrie, F. (1992) Transrectal ultrasound evaluation of local prostate cancer in patients treated with LHRH agonist and in combination therapy with flutamide. Urology, 39: 254-261. |
Prostate Cancer |
1992 |
|
131. Bélanger, A., Rong, P.M., Liu, S., Lavoie, L., Labrie, F. (1993) Characterization and measurement of prostate-specific antigen using monoclonal antibodies. Clin. Invest. Med., 16: 409-415. |
Prostate Cancer |
1993 |
|
132. Dupont, A., Cusan, L., Gomez, J.L., Koutsilieris, M., Suburu, R., Emond, J., Labrie, F. (1993) Combination therapy with Flutamide and the LHRH agonist [D-Trp6-des-Gly-NH2]LHRH ethylamide in stage C prostatic carcinoma. Br. J. Urol., 72: 629-634. |
Prostate Cancer |
1993 |
|
133. Dupont, A., Gomez, J.L., Cusan, L., Koutsilieris, M., Labrie, F. (1993) Response to Flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J. Urol., 150: 908-913. |
Prostate Cancer |
1993 |
|
134. Labrie, F. (1993) GNRH agonists in prostate cancer, in GnRH analogues - The State of the Art 1993, New York, Parthenon Publishing, pp 103-121. |
Prostate Cancer |
1993 |
|
135. Labrie, F. (1993) Intracrinology: its impact on prostate cancer. Curr. Opin. Urol., 3: 381-387. |
Prostate Cancer |
1993 |
|
136. Labrie, F. (1993) Mechanism of action and pure antiandrogenic properties of Flutamide. Cancer, 72: 3816-3827. |
Prostate Cancer |
1993 |
|
137. Labrie, F. (1993) Non-steroidal antiandrogens, in: Droz, J.P., Cvitkovic, E., Armand, J.P. et Khoury, S., eds: Handook of Chemotherapy in Clinical Oncology, London, Scientific Communication International Ltd., pp 389-391. |
Prostate Cancer |
1993 |
|
138. Labrie, F. (1993) Present status of endocrine therapy of prostate cancer. Eur. Urol. Today, 3: 10-11. |
Prostate Cancer |
1993 |
|
139. Labrie, F., Bélanger, A., Dupont, A., Luu-The, V., Simard, J., Labrie, C. (1993) Science behind total androgen blockade: from gene to combination therapy. Clin. Invest. Med., 16: 475-492. |
Prostate Cancer |
1993 |
|
140. Labrie, F., Bélanger, A., Simard, J., Labrie, C., Dupont, A. (1993) Combination therapy for prostate cancer. Endocrine and biologic basis of its choice as new standard first line therapy. Cancer, 71: 1059-1067. |
Prostate Cancer |
1993 |
|
141. Labrie, F., Dupont, A., Cusan, L., Gomez, J.-L., Diamond, P. (1993) Major advantages of "early" administration of endocrine combination therapy in advanced prostate cancer. Clin. Invest. Med., 16: 493-498. |
Prostate Cancer |
1993 |
|
142. Labrie, F., Dupont, A., Cusan, L., Gomez, J.L., Diamond, P., Koutsilieris, M., Suburu, R., Fradet, Y., Lemay, M., Tetu, B., Emond, J., Candas, B. (1993) Downstaging of localized prostate cancer by neoadjuvant therapy with Flutamide and Lupron. Clin. Invest. Med., 16: 499-509. |
Prostate Cancer |
1993 |
|
143. Labrie, F., Dupont, A., Simard, J., Luu-The, V., Bélanger, A. (1993) Intracrinology: the basis for the rational design of endocrine therapy at all stages of prostate cancer. Eur. Urol., 24 Suppl. 2: 94-105. |
Prostate Cancer |
1993 |
|
144. Labrie, F., Dupont, A., Suburu, R., Cusan, L., Gomez, J.L., Koutsilieris, M., Diamond, P., Emond, J., Lemay, M., Candas, B. (1993) Optimized strategy for detection of early stage, curable prostate cancer: role of prescreening with prostate-specific antigen. Clin. Invest. Med., 16: 425-439. |
Prostate Cancer |
1993 |
|
145. Martel, C., Trudel, C., Couet, J., Labrie, C., Bélanger, A., Labrie, F. (1993) Blockade of androstenedione-induced stimulation of androgen-sensitive parameters in the rat prostate by combination of Flutamide and 4-MA. Mol. Cell. Endocrinol., 91: 43-49. |
Prostate Cancer |
1993 |
|
146. Normand, T., Narod, S., Labrie, F., Simard, J. (1993) Detection of polymorphisms in the estradiol 17β-hydroxysteroid dehydrogenase II gene at the human EDH17B2 locus on 17q11-q21. Hum. Mol. Genet., 2: 479-483. |
Prostate Cancer |
1993 |
|
121. Bélanger, A., Candas, B., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Labrie, F. (1994) Changes in serum concentration of conjugated and unconjugated steroids in 40- to 80-year old men. J. Clin. Endocrinol. Metab., 79: 1086-1090. |
Prostate Cancer |
1994 |
|
122. Cusan, L., Gomez, J.L., Dupont, A., Diamond, P., Lemay, M., Moore, S., Labrie, F. (1994) Metastatic prostate cancer pulmonary nodules: beneficial effects of combination therapy and subsequent withdrawal of flutamide. Prostate, 24: 257-261. |
Prostate Cancer |
1994 |
|
123. Koutsilieris, M., Dupont, A., Gomez, J.L., Cusan, L., Suburu, R., Diamond, P., Labrie, F. (1994) Stratification of stage D2 prostate cancer patients by a disease aggressiveness score and its use in evaluating disease response and outcome to combination hormonal therapy (GnRH-A plus Flutamide). Anticancer Res., 14: 627-634. |
Prostate Cancer |
1994 |
|
124. Labrie, F. (1994) Intracrinology and Cancer Therapy. Science Watch, 5: 3-4. |
Prostate Cancer |
1994 |
|
125. Labrie, F. (1994) Les antiandrogènes dans le cancer de la prostate. La Lettre du Pharmacologue, 8: 190-195. |
Prostate Cancer |
1994 |
|
126. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to 342: 901-5, 1993]. Lancet, 343: 491. |
Prostate Cancer |
1994 |
|
127. Labrie, F. (1994) Prostate cancer [Letter to the Editor: Reply to Cheney re 343: 491-2, 1994]. Lancet, 343: 976-977. |
Prostate Cancer |
1994 |
|
128. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1994) Downstaging of early stage prostate cancer before radical prostatectomy: the first randomized trial of neoadjuvant combination therapy with Flutamide and a luteinizing hormone-releasing hormone agonist. Urology, 44: 29-37. |
Prostate Cancer |
1994 |
|
129. Labrie, F., Simard, J., Bélanger, A., Luu-The, V., Labrie, C. (1994) Molecular biology of the intracrine steroidogenic enzymes in the human prostate, in: Motta, M. et Serio, M., eds: Sex Hormones and Antihormones in Endocrine-Dependent Pathology: Basic and Clinical Aspects, New York, Elsevier, pp 77-92. |
Prostate Cancer |
1994 |
|
130. Sugimoto, K., Simard, J., Veilleux, R., Haagensen, D.E., Labrie, F. (1994) Inverse relationships between cell proliferation and basal or androgen-stimulated apolipoprotein D secretion in LNCaP human prostate cancer cells. J. Steroid Biochem. Mol. Biol., 51: 167-174. |
Prostate Cancer |
1994 |
|
108. Bélanger, A., Van Halbeek, H., Graves, H.C.B., Grandbois, K., Stamey, T.A., Lihua, H., Poppe, I., Labrie, F. (1995) Molecular mass and carbohydrate structure of prostate specific antigen: studies for establishment of an international PSA standard. Prostate, 27: 187-197. |
Prostate Cancer |
1995 |
|
109. Chen, C., Puy, L.A., Simard, J., Li, X., Singh, S.M., Labrie, F. (1995) Local and systemic reduction by topical Finasteride or Flutamide on hamster flank organ size and enzyme activity. J. Invest. Dermatol., 105: 678-682. |
Prostate Cancer |
1995 |
|
110. Labrie, F. (1995) Endocrine therapy of prostate cancer: optimal form and timing. J. Clin. Endocrinol. Metab., 80: 1066-1071. |
Prostate Cancer |
1995 |
|
111. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C. (1995) Intracrinologie: autonomie et liberté des tissus périphériques. Ann. Endocrinol. (Paris), 56: 23-29. |
Prostate Cancer |
1995 |
|
112. Labrie, F., Crawford, D.; (1995) Anti-androgens in treatment of prostate cancer. Lancet, 346: 1030-1031. |
Prostate Cancer |
1995 |
|
113. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Candas, B. (1995) Combination of screening and preoperative endocrine therapy: the potential for an important decrease in prostate cancer mortality. J. Clin. Endocrinol. Metab., 80: 2002-2013. |
Prostate Cancer |
1995 |
|
114. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Candas, B. (1995) Screening und Re-Screening des Prostatakarzinoms: Die Quebec-Studie, in Faul, P. et Altwein, J.E., eds: Screening des Prostatakarzinoms, Berlin, Springer-Verlag, pp 339-352. |
Prostate Cancer |
1995 |
|
115. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Suburu, R., Lemay, M., Tetu, B., Fradet, Y., Candas, B. (1995) Downstaging by combination therapy with flutamide and an LHRH agonist before radical prostatectomy. Cancer Surv. 23: 149-156. |
Prostate Cancer |
1995 |
|
116. Li, X., Singh, S.M., Côté, J., Laplante, S., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro evaluation of 4-substituted-N-(1,1-dimethylethyl)-3-oxo-4-androsten-17beta-carboxamides as 5alpha-reductase inhibitors and antiendrogens. J. Med. Chem., 38: 1456-1461. |
Prostate Cancer |
1995 |
|
117. Li, X., Singh, S.M., Labrie, F. (1995) Synthesis and in vitro activity of 17beta-(N-alkyl)formamido/ alkylamido-4-aza-/4-methyl-4-aza-3-oxo-5beta-androstan-3-ones as inhibitors of human 5alpha-reductase and antagonists on the androgen receptor. J. Med. Chem., 38: 1158-1173. |
Prostate Cancer |
1995 |
|
118. Li, X., Singh, S.M., Lourdusamy, M., Mérand, Y., Veilleux, R., Labrie, F. (1995) Synthesis and in vitro antiandrogenic activity of 17beta-hydroxy-17beta-(w-hydroxy/haloalkyn-1'-yl)-4-methyl-4-aza-3-oxo-5beta-androstan-(1-ene)-3-ones. Bioorg. Med. Chem. Lett., 5: 1061-1064. |
Prostate Cancer |
1995 |
|
119. Narod, S., Dupont, A., Cusan, L., Diamond, P., Gomez, J.L., Suburu, R., Labrie, F. (1995) The impact of family history on early detection of prostate cancer. Nature Medicine, 1: 99-101. |
Prostate Cancer |
1995 |
|
120. Sun, S., Narod, S., Aprikian, A., Ghadirian, P., Labrie, F. (1995) Androgen receptor and familial prostate cancer. Nature Medicine, 1: 848-849. |
Prostate Cancer |
1995 |
|
91. Azzi, A., Rehse, P.H., Zhu, D.-W., Campbell, R.L., Labrie, F., Lin, S.-X. (1996) Crystal structure of human estrogenic 17beta-hydroxysteroid dehydrogenase complexed with 17beta-estradiol. Nat. Struct. Biol., 3: 665-668. |
Prostate Cancer |
1996 |
|
92. Chen, C., Li, X., Singh, S.M., Bélanger, A., Labrie, F. (1996) Additive in vivo growth-inhibitory effects of Flutamide and Finasteride on androgen-sensitive Shionogi 115 carcinoma. Endocrine-Related Cancer, 3: 217-227. |
Prostate Cancer |
1996 |
|
93. Chen, C., Poulin, R., Labrie, F. (1996) Large Shionogi tumors lose their responsiveness to Flutamide treatment. J. Steroid Biochem. Mol. Biol., 58: 489-494. |
Prostate Cancer |
1996 |
|
94. Cusan, L., Gomez, J.L., Diamond, P., Candas, B., Labrie, F. (1996) Combined androgen blockade with GnRH analogues and Flutamide at all stages of prostate cancer (Chapter 15), in: Filicori, M. et Flamigni, C., eds: Treatment with GnRH Analogs: Controversies and Prospectives, New-York, The Parthenon Publishing Group, pp 125-137. |
Prostate Cancer |
1996 |
|
95. Dufort, I., Soucy, P., Labrie, F., Luu-The, V. (1996) Molecular cloning of human type 3 3alpha-hydroxysteroid dehydrogenase that differs from 20alpha-hydroxysteroid dehydrogenase by seven amino acids. Biochem. Biophys. Res. Commun., 228: 474-479. |
Prostate Cancer |
1996 |